The pharmaceutical supply chain has shifted from a relatively stable model to an uncertain, globally interconnected system driven by events revealing systemic vulnerabilities. Historically, disruptions were short-term and isolated (e.g., natural disasters, strikes or demand spikes) causing manageable delays that were seen as exceptions.